Results 131 to 140 of about 911,773 (309)
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS
Hepatology, EarlyView., 2022 The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.Alexander Queck, Louise Schwierz, Wenyi Gu, Philip G. Ferstl, Christian Jansen, Frank E. Uschner, Michael Praktiknjo, Johannes Chang, Maximilian J. Brol, Filippo Schepis, Manuela Merli, Christian P. Strassburg, Jennifer Lehmann, Carsten Meyer, Jonel Trebicka +14 morewiley +1 more sourceSerosurvey for HIV, Hepatitis B, and C Viruses Among Apparently Healthy Students of Federal Polytechnic Idah and its Environs [PDF]
, 2023 Joseph Oyiguh Abraham, Cornelius Arome Omatola, Martin-Luther Oseni Okolo, Ruth Foluke Aminu, Emmanuel Edegbo, Olubunmi Marvelous Emurotu, Danjuma Muhammed, Jesse Joseph Chock, Helen Ojomachenwu Ocean, Yahaya Ocholi +9 moreopenalex +1 more sourceGlobal prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
The Lancet Gastroenterology and Hepatology, 2017 S. Blach, S. Zeuzem, M. Manns, I. Altraif, Ann-Sofi Duberg, D. Muljono, I. Waked, S. Alavian, Mei‐Hsuan Lee, F. Negro, F. Abaalkhail, A. Abdou, Maheeba Abdulla, A. Rached, I. Aho, U. Akarca, I. Ghazzawi, S. Kaabi, Faryal Al Lawati, Khalid Al Namaani, Y. A. Serkal, Said A. Al-Busafi, Layla Al-Dabal, S. Aleman, A. Alghamdi, A. Aljumah, H. Al-Romaihi, M. Andersson, V. Arendt, P. Arkkila, A. Assiri, O. Baatarkhuu, A. Bane, Z. Ben‐Ari, C. Bergin, F. Bessone, F. Bihl, A. Bizri, M. Blachier, A. Blasco, C. Mello, P. Bruggmann, C. Brunton, F. Calinas, H. Chan, A. Chaudhry, H. Cheinquer, Chien-Jen Chen, R. Chien, M. Choi, P. Christensen, W. Chuang, V. Chulanov, L. Cisneros, M. Clausen, M. Cramp, A. Craxì, E. Croes, O. Dalgard, J. Daruich, V. Ledinghen, G. Dore, M. El-Sayed, G. Ergör, G. Esmat, C. Estes, K. Falconer, E. Farag, M. L. Ferraz, P. Ferreira, R. Flisiak, S. Fraňková, I. Gamkrelidze, E. Gane, J. García-Samaniego, A. Khan, I. Gountas, A. Goldiş, M. Gottfredsson, J. Grebely, M. Gschwantler, M. Pessoa, J. Gunter, B. Hajarizadeh, O. Hajelssedig, S. Hamid, W. Hamoudi, A. Hatzakis, S. Himatt, H. Hofer, I. Hrstic, Y. Hui, B. Hunyady, R. Idilman, W. Jafri, R. Jahis, N. Janjua, P. Jarčuška, A. Jēruma, J. Jónasson, Y. Kamel, J. Kao, S. Kaymakoğlu, D. Kershenobich, J. Khamis, Young Sik Kim, L. Kondili, Z. Koutoubi, M. Krajden, H. Krarup, M. Lai, W. Laleman, W. Lao, D. Lavanchy, P. Lázaro, H. Leleu, O. Lesi, L. A. Lesmana, Michael Li, V. Liakina, Y. Lim, B. Lukšić, A. Mahomed, M. Maimets, M. Makara, A. Malu, R. Marinho, P. Marotta, S. Mauss, M. Memon, M. Correa, N. Méndez-Sánchez, S. Merat, Ammal M. Metwally, R. Mohamed, Christophe Moreno, F. Mourad, B. Müllhaupt, K. Murphy, H. Nde, R. Njouom, D. Nonković, S. Norris, S. Obekpa, S. Oguche, S. Olafsson, M. Oltman, O. Omede, C. Omuemu, O. Opare-Sem, A. Øvrehus, S. Owusu-Ofori, T. Oyunsuren, G. Papatheodoridis, K. Pasini, K. Peltekian, R. Phillips, N. Pimenov, H. Poustchi, N. Prabdial-Sing, H. Qureshi, A. Ramji, D. Razavi-Shearer, K. Razavi‐Shearer, B. Redae, H. Reesink, E. Ridruejo, S. Robbins, L. Roberts, S. Roberts, W. Rosenberg, F. Roudot-thoraval, S. Ryder, R. Safadi, O. Sagalova, R. Salupere, F. Sanai, J. Ávila, V. Saraswat, R. Sarmento-Castro, C. Sarrazin, J. Schmelzer, I. Schréter, C. Seguin-Devaux, Samir R. Shah, A. Sharara, Manik Sharma, A. Shevaldin, G. Shiha, W. Sievert, M. Sonderup, K. Souliotis, D. Speičienė, J. Sperl, P. Stärkel, R. Stauber, C. Stedman, D. Struck, T. Su, V. Sypsa, S. Tan, J. Tanaka, A. Thompson, I. Tolmane, K. Tomasiewicz, J. Valantinas, P. Damme, A. J. Meer, I. Thiel, H. Vlierberghe, A. Vince, W. Vogel, H. Wedemeyer, N. Weis, V. Wong, C. Yaghi, A. Yosry, M. Yuen, E. Yunihastuti, Aasim Yusuf, E. Zuckerman, H. Razavi +221 moresemanticscholar +1 more sourceCytosolic Phosphoenoylpyruvate Carboxykinase Deficiency: Clinical, Biochemical, and Genetic Features of Five Non‐Finnish Patients
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT
Cytosolic phosphoenoylpyruvate carboxykinase (PEPCK‐C) is an essential, rate‐limiting enzyme in the gluconeogenesis pathway. PEPCK‐C deficiency presents with hypoglycaemia, hyperlactataemia and hepatopathy, and was first reported in association with bi‐allelic PCK1 variants in 2014.Isaac Bernhardt, Polona Le Quesne Stabej, Claire Hart, Mark De Hora, Sarah Hulley, Mark Anderson, Harry G. Leitch, Hugh Lemonde, Bryony Ryder, James Davison +9 morewiley +1 more sourceEffect of Hepatitis C Virus Infection in Patients With Cancer: Addressing a Neglected Population [PDF]
, 2015 Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed O. Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam Raad, Dimitrios P. Kontoyiannis +9 moreopenalex +1 more sourceOptimizing the dengue virus infection mouse model: Comparing different backgrounds and infection route for enhanced stability
Animal Models and Experimental Medicine, EarlyView.Optimized dengue fever animal model: IFNAR−/− BALB/c mice with intraperitoneal injection. Background screening: Between IFNAR−/− (BALB/c, C57BL/6) and AG129 mice, IFNAR−/−BALB/c exhibited the most severe symptoms: (1) highest weight loss and clinical scores; (2) peak viremia (5.44 log10 RNA copies/mL, day 4); (3) significant organ damage (liver/brain ...Dan Liao, Ming Zhong, Wenjiang Zheng, Zhendong Guo, Ye Zhou, Qiuhong Li, Lijuan Qiu, Liangwen Yu, Haishan Long, Geng Li +9 morewiley +1 more sourceThe NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression
Hepatology, EarlyView., 2022 Loss of NOX4 in HCC tumor cells induces metabolic reprogramming in a Nrf2/MYC‐dependent manner to promote HCC progression. Abstract Background and Aims
The NADPH oxidase NOX4 plays a tumor‐suppressor function in HCC. Silencing NOX4 confers higher proliferative and migratory capacity to HCC cells and increases their in vivo tumorigenic potential in ...Irene Peñuelas‐Haro, Rut Espinosa‐Sotelo, Eva Crosas‐Molist, Macarena Herranz‐Itúrbide, Daniel Caballero‐Díaz, Ania Alay, Xavier Solé, Emilio Ramos, Teresa Serrano, María L. Martínez‐Chantar, Ulla G. Knaus, José M. Cuezva, Antonio Zorzano, Esther Bertran, Isabel Fabregat +14 morewiley +1 more sourceMucin Glycoprotein Nanoparticles Enable a Selective Antisense Therapy for Oncogenic MicroRNAs
Advanced NanoBiomed Research, EarlyView.Mucin glycoproteins are turned into nanoparticles by employing synthetic DNA strands, which have a dual function: they stabilize the nanoparticles and act as binding sites for intracellular miRNA‐21. Thus, upon internalization into tumor cells, these mucin nanoparticles can deplete miRNA‐21 from the cytosol, which induces apoptosis in vitro and in vivo.Ceren Kimna, Thomas Mayer, Di Zhang, Matthias Marczynski, Carolin A. Rickert, Fabio Henkel, Lennart J. K. Weiss, Friedrich C. Simmel, Yuxia Luan, Oliver Lieleg +9 morewiley +1 more sourceMitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis
Hepatology, EarlyView., 2022 Adaptive mitochondrial mechanisms allow mitochondrial resilience and prevent the worsening of fibrosis, while deregulation of these mechanisms promotes the progression from no/minimal‐mild (F0‐F2) fibrosis to advanced fibrosis and cirrhosis (F3‐F4). Abstract Background and Aims
Hepatitis B virus (HBV) infection causes oxidative stress (OS) and alters ...Dimitri Loureiro, Issam Tout, Stéphanie Narguet, Cheikh Mohamed Bed, Morgane Roinard, Ahmad Sleiman, Nathalie Boyer, Nathalie Pons‐Kerjean, Corinne Castelnau, Nathalie Giuly, Dorothy Tonui, Vassili Soumelis, Jamel El Benna, Patrick Soussan, Richard Moreau, Valérie Paradis, Abdellah Mansouri, Tarik Asselah +17 morewiley +1 more source
